InvestorQ : Why Divis lab share underperforming? I can expect 2650 target for July F&O series?
Ds Ranganath made post
F&O

Why Divis lab share underperforming? I can expect 2650 target for July F&O series?

Answer
image
Arusha Ray answered.
10 months ago
Follow

The stock is a solid player although there have been some concerns with the FDA at this point. However, Divi is likely to benefit from the overall rerating of the pharma sector in India. You can take a view accordingly.

1 Views